#Israel #Immunotherapy #Compugen #Holon #CGEN

Compugen to Release Third Quarter 2025 Results

Compugen Ltd., the innovative cancer immunotherapy company renowned for its application of artificial intelligence in drug discovery, is set to unveil its financial results for the third quarter of 2025 on November 10, 2025. This announcement comes as the company continues to pave the way in the field of predictive computational drug discovery.

Important Announcement Details

On that day, prior to the opening of U.S. financial markets, Compugen will provide insights into its latest financial performance. The management team will host a conference call and a webcast at 8:30 AM ET, offering shareholders and stakeholders an opportunity to gain detailed information on the company's earnings, advancements, and future directions.

For those wishing to join the live conference call, local U.S. attendees can dial 1-866-744-5399, while international participants should call +972-3-918-0644. Moreover, a live webcast of the call can be accessed directly through the Compugen website, providing a convenient option for those unable to join via telephone.

About Compugen

Compugen is at the forefront of cancer research, leveraging its proprietary predictive AI/ML computational platform known as Unigen™. This sophisticated tool enhances the identification of new drug targets and biological pathways, crucial for developing potent cancer immunotherapies. Notably, Compugen is advancing two promising candidates through Phase 1 clinical trials. These are:

• - COM701: A potential first-in-class anti-PVRIG antibody.
• - COM902: A potential best-in-class antibody targeting TIGIT, intended for treating solid tumors.

Additionally, a bispecific antibody utilizing the TIGIT component from COM902, named Rilvegostomig, is undergoing Phase 3 evaluation by AstraZeneca, facilitated by a licensing agreement aimed at further developing bispecific and multispecific antibodies.

Compugen is also working on another promising candidate, GS-0321, an anti-IL-18 binding protein antibody, which is currently licensed to Gilead and in Phase 1 development. This diverse portfolio illustrates Compugen’s commitment to exploring new avenues in cancer treatment, targeting different mechanisms to stimulate the immune system against malignancies.

With its headquarters located in Holon, Israel, and an office in San Francisco, California, Compugen is publicly traded on both the Nasdaq and Tel Aviv Stock Exchange under the ticker symbol CGEN. The company's share performance is closely monitored by investors as it marks significant milestones in the therapeutic landscape of oncology.

As the countdown to the financial results meeting begins, stakeholders eagerly await insights that will shape the understanding of Compugen's trajectory in the competitive field of cancer immunotherapy. Prepare to learn about new developments, advancements in existing programs, and what the future holds for this pioneering company.

For further questions or inquiries, you can reach out to Dr. Yvonne Naughton, Vice President and Head of Investor Relations and Corporate Communications at Compugen, via email or by phone, ensuring that communication remains open for both investors and interested parties alike.